IfPA’s Patient Access Policy Blog

Keeping Asthma Medication within Patients’ Reach

A new bureaucratic obstacle could make it even harder for asthma patients to get the medicine they need. For several years now, high cost-sharing has

Read More

Trials Data Raises Hopes in Cystic Fibrosis Community

Promising clinical trials data has excited patients with cystic fibrosis and their families.  But will access barriers dash their hopes for more and better treatment

Read More

IfPA Offers the Physician’s Perspective on Oncology Value Models

What is good value in terms of cancer treatment?  The question, amid rising cancer care costs, has prompted a surge of oncology value models in

Read More

Summit on Biologics and Biosimilars Tackles Choice, Switching & Patient Access

Physicians and patients are no longer asking if a biological medicine is the best choice, but – more likely – which biological medicine is the

Read More

New AfPA Video Examines “The Interchangeability Promise”

First came biologics, then biosimilars.  And soon, explains a newly released video from The Alliance for Patient Access, patients can expect interchangeable biosimilars.  According to

Read More

How to Achieve Hepatitis Elimination

Eliminating hepatitis B and C can be done, experts agree. And this week, a new report from the National Academies of Sciences, Engineering, and Medicine

Read More

Access Worries Persist after ICER’s Arthritis Report, Meeting

A drug pricing watchdog group had its final say Friday on targeted arthritis treatments – and it may not be good news for patients. The

Read More

Will Political Finger-pointing Dampen Zika Vaccine Efforts?

A vaccine for Zika virus is in the works with the potential to halt the devastating disease that’s spread to more than 5,000 people and

Read More

Can the Gas Company’s Model Help Seniors Manage Rx Co-pays?

Senior citizens can face crippling out-of-pocket costs for their Medicare Part D prescription drugs. But now the University of Pennsylvania’s Perelman School of Medicine has

Read More

Cardiac Meds Cut Patients’ Heart Attack Risk – Or Your Money Back

Cholesterol-lowering drugs known as PCSK9 inhibitors can reduce the risk of heart, stroke and cardiovascular death by 20 percent, new research confirms.  And if patients

Read More
Back to Top